Table 1.
Ongoing clinical trials evaluating growth factor inhibition in pancreatic cancer.
| Drugs/Inhibitors | Growth factor target | Number of ongoing clinical trials with results* | Status of clinical trials | Clinical trial number |
|---|---|---|---|---|
| Nab-Paclitaxel | IGF-1R | 142 | 41 active, not recruiting 101 recruiting | Such as NCT03316599, NCT03520790, NCT02827201, NCT02210559, NCT02047513, NCT03086369, NCT02717091, NCT02481635, NCT03252808, NCT02427841, NCT04808687, NCT02340117, NCT03929094, NCT03850769, NCT03941093, NCT03885219, NCT03652428, NCT03636308, NCT04498689, |
| Bevacizumab | VEGF | 13 | 7 active, not recruiting6 recruiting | NCT03387098, NCT03329248, NCT03136406, NCT03586869, NCT03376659, NCT01229943, NCT04299880 NCT03351296, NCT03597581, NCT03193190, NCT02820857, NCT04430842, NCT03597581 |
| Sunitinib | VEGFR, PDGFR, | 4 | 4 recruiting | NCT02230176, NCT02282059, NCT02465060, NCT03878524, |
| Nintedanib | VEGFR, FGFR, PDGFR | 1 | 1 recruiting | NCT02902484 |
| Erlotinib | EGFR | 6 | 4 active, not recruiting 2 recruiting | NCT01013649, NCT00878163, NCT01660971, NCT02737228 NCT04136132, NCT03878524 |
| Cetuximab | EGFR | 4 | 3 active, not recruiting 1 recruiting | NCT03992664, NCT03319459, NCT01420874 NCT03785249 |
| Imatinib | PDGFR | 1 | 1 recruiting | NCT03878524 |
| Pamrevlumab (FG-3019) | CTGF | 2 | 1 active, not recruiting 1 recruiting | NCT02210559 NCT03941093 |
| Larotrectinib | NGF | 1 | 1 recruiting | NCT02465060 |
| Ficlatuzumab | HGF/c-MET | 1 | 1 active, not recruiting | NCT03316599 |
| Crizotinib | HGF/c-MET | 2 | 2 recruiting | NCT02465060, NCT02568267 |
*Studies could involve treatment alone or in combination with other therapeutic strategies.